New Targeted Therapies for Bone Metastases

Allan Lipton, Luis Costa, Paul Sieber, William C. Dougall, Ada Braun

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A number of targeted agents under investigation or in development have shown promise in the treatment or prevention of bone metastases. Among them is denosumab (XGEVA, Amgen Inc.), a fully human monoclonal antibody targeting the RANK ligand (RANKL) pathway that was approved on 18 November 2010 in the United States (Amgen XGEVA [denosumab] prescribing information, 2012). Denosumab has been proven superior to zoledronic acid in preserving skeletal function and integrity by preventing skeletal complications among patients with bone metastases from solid tumors. Denosumab has demonstrated prolongation of bone metastasis-free survival in men with castration-resistant prostate cancer and is being investigated for this outcome in women with early-stage breast cancer. Another study is prospectively evaluating a potential prolongation of overall survival with denosumab in patients with metastatic lung cancer. Also currently in development are numerous targeted agents that impact the function of the various growth factors released from the bone matrix that stimulate tumor growth, bone destruction, and lead to bone metastases.

Original languageEnglish (US)
Title of host publicationBone Metastases
Subtitle of host publicationA translational and Clinical Approach
EditorsVassilios Vassiliou, Edward Chow, Dimitrios Kardamakis
Pages235-246
Number of pages12
Edition1
DOIs
StatePublished - Mar 4 2014

Publication series

NameCancer Metastasis - Biology and Treatment
Number1
Volume21
ISSN (Print)1568-2102

Fingerprint

Neoplasm Metastasis
Bone and Bones
zoledronic acid
RANK Ligand
Therapeutics
Bone Matrix
Survival
Castration
Bone Development
Lung Neoplasms
Neoplasms
Prostatic Neoplasms
Intercellular Signaling Peptides and Proteins
Monoclonal Antibodies
Denosumab
Breast Neoplasms

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Lipton, A., Costa, L., Sieber, P., Dougall, W. C., & Braun, A. (2014). New Targeted Therapies for Bone Metastases. In V. Vassiliou, E. Chow, & D. Kardamakis (Eds.), Bone Metastases: A translational and Clinical Approach (1 ed., pp. 235-246). (Cancer Metastasis - Biology and Treatment; Vol. 21, No. 1). https://doi.org/10.1007/978-94-007-7569-5_12
Lipton, Allan ; Costa, Luis ; Sieber, Paul ; Dougall, William C. ; Braun, Ada. / New Targeted Therapies for Bone Metastases. Bone Metastases: A translational and Clinical Approach. editor / Vassilios Vassiliou ; Edward Chow ; Dimitrios Kardamakis. 1. ed. 2014. pp. 235-246 (Cancer Metastasis - Biology and Treatment; 1).
@inbook{258e016733fa48b6b3636fb66db96f50,
title = "New Targeted Therapies for Bone Metastases",
abstract = "A number of targeted agents under investigation or in development have shown promise in the treatment or prevention of bone metastases. Among them is denosumab (XGEVA, Amgen Inc.), a fully human monoclonal antibody targeting the RANK ligand (RANKL) pathway that was approved on 18 November 2010 in the United States (Amgen XGEVA [denosumab] prescribing information, 2012). Denosumab has been proven superior to zoledronic acid in preserving skeletal function and integrity by preventing skeletal complications among patients with bone metastases from solid tumors. Denosumab has demonstrated prolongation of bone metastasis-free survival in men with castration-resistant prostate cancer and is being investigated for this outcome in women with early-stage breast cancer. Another study is prospectively evaluating a potential prolongation of overall survival with denosumab in patients with metastatic lung cancer. Also currently in development are numerous targeted agents that impact the function of the various growth factors released from the bone matrix that stimulate tumor growth, bone destruction, and lead to bone metastases.",
author = "Allan Lipton and Luis Costa and Paul Sieber and Dougall, {William C.} and Ada Braun",
year = "2014",
month = "3",
day = "4",
doi = "10.1007/978-94-007-7569-5_12",
language = "English (US)",
isbn = "9789400775688",
series = "Cancer Metastasis - Biology and Treatment",
number = "1",
pages = "235--246",
editor = "Vassilios Vassiliou and Edward Chow and Dimitrios Kardamakis",
booktitle = "Bone Metastases",
edition = "1",

}

Lipton, A, Costa, L, Sieber, P, Dougall, WC & Braun, A 2014, New Targeted Therapies for Bone Metastases. in V Vassiliou, E Chow & D Kardamakis (eds), Bone Metastases: A translational and Clinical Approach. 1 edn, Cancer Metastasis - Biology and Treatment, no. 1, vol. 21, pp. 235-246. https://doi.org/10.1007/978-94-007-7569-5_12

New Targeted Therapies for Bone Metastases. / Lipton, Allan; Costa, Luis; Sieber, Paul; Dougall, William C.; Braun, Ada.

Bone Metastases: A translational and Clinical Approach. ed. / Vassilios Vassiliou; Edward Chow; Dimitrios Kardamakis. 1. ed. 2014. p. 235-246 (Cancer Metastasis - Biology and Treatment; Vol. 21, No. 1).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - New Targeted Therapies for Bone Metastases

AU - Lipton, Allan

AU - Costa, Luis

AU - Sieber, Paul

AU - Dougall, William C.

AU - Braun, Ada

PY - 2014/3/4

Y1 - 2014/3/4

N2 - A number of targeted agents under investigation or in development have shown promise in the treatment or prevention of bone metastases. Among them is denosumab (XGEVA, Amgen Inc.), a fully human monoclonal antibody targeting the RANK ligand (RANKL) pathway that was approved on 18 November 2010 in the United States (Amgen XGEVA [denosumab] prescribing information, 2012). Denosumab has been proven superior to zoledronic acid in preserving skeletal function and integrity by preventing skeletal complications among patients with bone metastases from solid tumors. Denosumab has demonstrated prolongation of bone metastasis-free survival in men with castration-resistant prostate cancer and is being investigated for this outcome in women with early-stage breast cancer. Another study is prospectively evaluating a potential prolongation of overall survival with denosumab in patients with metastatic lung cancer. Also currently in development are numerous targeted agents that impact the function of the various growth factors released from the bone matrix that stimulate tumor growth, bone destruction, and lead to bone metastases.

AB - A number of targeted agents under investigation or in development have shown promise in the treatment or prevention of bone metastases. Among them is denosumab (XGEVA, Amgen Inc.), a fully human monoclonal antibody targeting the RANK ligand (RANKL) pathway that was approved on 18 November 2010 in the United States (Amgen XGEVA [denosumab] prescribing information, 2012). Denosumab has been proven superior to zoledronic acid in preserving skeletal function and integrity by preventing skeletal complications among patients with bone metastases from solid tumors. Denosumab has demonstrated prolongation of bone metastasis-free survival in men with castration-resistant prostate cancer and is being investigated for this outcome in women with early-stage breast cancer. Another study is prospectively evaluating a potential prolongation of overall survival with denosumab in patients with metastatic lung cancer. Also currently in development are numerous targeted agents that impact the function of the various growth factors released from the bone matrix that stimulate tumor growth, bone destruction, and lead to bone metastases.

UR - http://www.scopus.com/inward/record.url?scp=84896818189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896818189&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-7569-5_12

DO - 10.1007/978-94-007-7569-5_12

M3 - Chapter

AN - SCOPUS:84896818189

SN - 9789400775688

T3 - Cancer Metastasis - Biology and Treatment

SP - 235

EP - 246

BT - Bone Metastases

A2 - Vassiliou, Vassilios

A2 - Chow, Edward

A2 - Kardamakis, Dimitrios

ER -

Lipton A, Costa L, Sieber P, Dougall WC, Braun A. New Targeted Therapies for Bone Metastases. In Vassiliou V, Chow E, Kardamakis D, editors, Bone Metastases: A translational and Clinical Approach. 1 ed. 2014. p. 235-246. (Cancer Metastasis - Biology and Treatment; 1). https://doi.org/10.1007/978-94-007-7569-5_12